id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S12828 R48303 |
Thomas (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2021 | Skeletal malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
2.14 [0.09;53.55] C excluded (control group) |
1/71 0/50 | 1 | 71 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12830 R48315 |
Thomas (Oxcarbazepine) (Controls unexposed, sick), 2021 | Skeletal malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 2.41 [0.22;27.00] C | 1/71 2/340 | 3 | 71 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6071 R15804 |
Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 | Skeletal abnormalities | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 19.83 [0.86;455.05] C | 0/7 2/647 | 2 | 7 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6096 R35921 |
Artama (Oxcarbazepine), 2005 | Certain musculoskeletal deformities and Other anomalies of limbs | 1st trimester | retrospective cohort (registry) | unexposed, sick | Adjustment: No | 0.63 [0.04;11.12] C | 0/99 7/939 | 7 | 99 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 3 studies | 2.81 [0.46;17.19] | 12 | 177 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Oxcarbazepine) (Controls unexposed, sick; 2: Oxcarbazepine) (Controls exposed to Lamotrigine, sick; 3: Oxcarbazepine;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 12828